Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Solid H1 performance despite continued impact of COVID-19
Group¹
USD million
Q2
Change vs. PY
H1
Change vs. PY
2021
2021
% USD
% cc
% USD
% cc
Net Sales
12,956
14
9
25,367
7
3
Core Operating income
4,345
18
13
8,302
6
2
Operating income
3,479
48
41
5,894
16
12
Net Income
2,895
55
49
4,954
23
19
Core EPS (USD)
1.66
22
16
3.17
9
5
EPS (USD)
1.29
57
52
2.20
24
24
21
Free Cash Flow
4,235
17
5,832
3
Q2 ex. PY forward purchasing de-stocking²: Sales +5%; Core Oplnc +4%
1. Core results, constant currencies and free cash flow are non-IFRS measures. Further details regarding non-IFRS measures can be found starting on page 48 of the Condensed Financial Report. 2. Growth excluding prior year COVID-19
related forward purchasing reversal is a non-IFRS measure, an explanation for this measure can be found on page 61 of the Condensed Interim Financial Report.
All % growth relate to cc unless otherwise stated.
33 Investor Relations | Q2 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation